P853 BERBERINE WITH ALFA LIPOIC ACID (ALA) IN NON ALCOHOLIC STEATO-HEPATITIS (NASH). A RANDOMIZED DOUBLE BLINDED PLACEBO CONTROL TRIAL. A CLINICAL PILOT – THE BANISH TRIAL

Background: Postoperative sore throat (POST) is considered to be quite common complaint. Its symptoms tend to improve with time, but use of oral zinc lozenge has been shown to reduce the incidence and severity of POST. The aim of the present study was to find the efficacy of oral zinc sulfate, given 30 min preoperatively, in reducing POST, primarily caused by endotracheal intubation, till 24 hours after surgery. Method: A prospective, randomized, double-blinded, placebo-control-trial study was conducted on 80 patients, further divided into two groups of 40 patients each, between the age group of 18-60 years, of either gender, in Super Specialty Hospital, GMC Jammu, over a period of 6-months. The two groups received either dispersible zinc tablet or a placebo. The severity of POST was graded on a 4-point scale ranging from 0 to 3 and evaluation was repeated at 30 min, 2, 4, and 24 hour, postoperatively. Results: The difference in severity of sore throat was found to be statistically significant at all evaluation time intervals, except at 24 hours, which was quite lower in Zinc group. The overall incidence of POST in Zinc group was 26.3%, which was significantly higher at 50% in placebo group. Conclusion: A dose 40 mg zinc dispersible tablet, equivalent to 40 mg elemental zinc, given 30 min before surgery, effectively reduced the incidence and severity of POST. Keywords: Post Operative Sore Throat, Oral Zinc Lozenge, Endotracheal Intubation.

Download Full-text

Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial

PLoS ONE ◽

10.1371/journal.pone.0174608 ◽

2017 ◽

Vol 12 (4) ◽

pp. e0174608 ◽

Cited By ~ 13

Author(s):

Piyawat Komolmit ◽

Kriangsak Charoensuk ◽

Kessarin Thanapirom ◽

Sirinporn Suksawatamnuay ◽

Panarat Thaimai ◽

...

Keyword(s):

Vitamin D ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Vitamin D Deficiency ◽

Chronic Hepatitis C ◽

Placebo Control Trial ◽

Placebo Control ◽

Dpp Iv ◽

Double Blinded

Download Full-text

Faculty Opinions recommendation of Efficacy of high-intensity laser therapy in the treatment of chronic neck pain: a randomized double-blind placebo-control trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726184991.793540079 ◽

2017 ◽

Author(s):

Paul White

Keyword(s):

Neck Pain ◽

Laser Therapy ◽

High Intensity ◽

Chronic Neck Pain ◽

Placebo Control Trial ◽

Placebo Control ◽

Double Blind ◽

Double Blind Placebo ◽

High Intensity Laser ◽

Intensity Laser

Download Full-text

Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530320666200506081407 ◽

2020 ◽

Vol 20 (9) ◽

pp. 1531-1534 ◽

Cited By ~ 1

Author(s):

Mamdouh R. El-Nahas ◽

Ghada Elkannishy ◽

Hala Abdelhafez ◽

Enas T. Elkhamisy ◽

Amr A. El-Sehrawy

Keyword(s):

Peripheral Neuropathy ◽

Lipoic Acid ◽

Diabetic Peripheral Neuropathy ◽

Study Groups ◽

Controlled Study ◽

Alpha Lipoic Acid ◽

Disability Score ◽

Perception Threshold ◽

Outcome Parameters ◽

Double Blinded

Background: Alpha-lipoic acid (ALA) was used in the treatment of diabetic peripheral neuropathy (DPN) using different routes, doses and treatment durations. The aim of this work is to assess the efficacy of oral 600mg ALA twice daily over 6 months in the treatment of patients with DPN. Methods: This is a prospective, single-center, double-blinded, placebo-controlled study conducted at the outpatient clinic of Mansoura Specialized Hospital, Mansoura University. A total of 200 patients with DPN were randomly assigned to add on treatment with either oral 600mg twice daily ALA (n=100) or placebo (n=100) for 6 months. Treatment outcome was assessed using vibration perception threshold (VPT), neurological symptom score (NSS), neurological disability score (NDS), and visual analog scale (VAS) for pain at baseline and at each visit (1, 3 and 6 months) after the start of treatment. Results: Comparison between the study groups regarding the baseline data revealed no statistically significant differences. with respect to the outcome parameters, no significant differences were found between the studied groups at baseline. However, in subsequent visits, ALA-treated patients had significantly better results regarding almost all the outcome parameters (NSS, NDS, VAS, VPT). Mild nausea was reported in 6 patients. None of the studied patients discontinued treatment. Conclusions: Oral 600mg ALA twice-daily treatment for DPN over 6 months is effective, safe and tolerable.

Download Full-text